| 21948233 |
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Heuckmann, JM,
Hölzel, M,
Sos, ML,
Heynck, S,
Balke-Want, H,
Koker, M,
Peifer, M,
Weiss, J,
Lovly, CM,
Grütter, C,
Rauh, D,
Pao, W,
Thomas, RK
|
Clin. Cancer Res. |
2011 |
| 18923525 |
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, RE,
Sanda, T,
Hanna, M,
Fröhling, S,
Luther, W,
Zhang, J,
Ahn, Y,
Zhou, W,
London, WB,
McGrady, P,
Xue, L,
Zozulya, S,
Gregor, VE,
Webb, TR,
Gray, NS,
Gilliland, DG,
Diller, L,
Greulich, H,
Morris, SW,
Meyerson, M,
Look, AT
|
Nature |
2008 |
| 21791641 |
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
Sasaki, T,
Koivunen, J,
Ogino, A,
Yanagita, M,
Nikiforow, S,
Zheng, W,
Lathan, C,
Marcoux, JP,
Du, J,
Okuda, K,
Capelletti, M,
Shimamura, T,
Ercan, D,
Stumpfova, M,
Xiao, Y,
Weremowicz, S,
Butaney, M,
Heon, S,
Wilner, K,
Christensen, JG,
Eck, MJ,
Wong, KK,
Lindeman, N,
Gray, NS,
Rodig, SJ,
Jänne, PA
|
Cancer Res. |
2011 |